 |
Prospector
Profile
07.1643
|
| |
| Isis Pharmaceuticals, Inc. |
NAICS |
541710 |
| 1896 Rutherford Road
Carlsbad, CA 92008 |
Description |
Biotechnology |
| (760) 931-9200 |
Employees |
274 |
| http://www.isispharm.com/ |
Revenue |
(mil) |
24.5320 |
| |
Income |
(mil) |
-45.9030 |
| |
Assets |
(mil) |
255.9070 |
| |
Liability |
(mil) |
187.3440 |
| |
(for the year ended 2006-12-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Isis Pharmaceuticals, Inc. had a net loss of $105.3 million on revenues of $38.63 million for the three months ended September 30, 2007, substantially higher than the $12.11 million net loss on $3.25 million in revenues reported during the three months ended September 30, 2006. For the nine months ended September 30, 2007, the Company had a $129.35 million net loss, much higher than the $31.76 million net loss incurred during the nine months ended September 30, 2006. The Company's balance sheet at September 30, 2007, showed an accumulated deficit of $820.79 million and only $213,003 in stockholders' equity.
|
| |
|
Intellectual Property:
The Company owns or exclusively licenses more than 1,500 issued patents, which represents the largest and most valuable antisense and RNA-oriented patent estate in the pharmaceutical industry. The principal purpose of its intellectual property portfolio is to protect the Company's products and those of its partners. In addition, the intellectual property is a strategic asset that it is exploiting to generate near-term revenues and will also provide with revenue in the future. The intellectual property portfolio enables the Company to expand its pipeline by granting to other companies limited access to antisense technology through licenses. The Company was recently awarded several key U.S. patents, including a patent protecting its antisense drugs with modified sugars until 2023, a patent that broadly covers certain chemical modifications of oligonucleotides and the first issued patent protecting its core Ibis business. Additionally, the European Patent Office upheld on appeal a key Isis patent covering antisense drugs with gapmer structures. [SEC Filing 10-K 03-16-07]
|
| |
|
Description:
The biopharmaceutical company engages in RNA-based drug discovery and development for its product pipeline and for its partners.
|
| |
|
Officers:
Stanley T. Crooke (Chair & CEO); B. Lynne Parshall (EVP, CFO, Sec. & Dir.); Jeffrey M. Jonas (EVP); C. Frank Bennett (SVP); Mark K. Wedel (SVP & Chief Medical Officer)
|
| |
|
Auditor:
Ernst & Young LLP
|
| |
|
Securities:
Common Stock-Symbol ISIS; Nasdaq;
86,950,330 common shares outstanding as of November 5, 2007.
|
| |
| |
| |
| return to main page |
|
|
